Indications › Type 2 diabetes › lixisenatide
lixisenatide in type 2 diabetes
lixisenatide is approved in the US for type 2 diabetes, and has 44 trials on file here in this condition. 42 of them are phase 3 or later. The next scheduled result is 2026-09-18.
44 registered trials study lixisenatide (Soliqua, Adlyxin) in type 2 diabetes, 3 of them still active. The next is due to report 2026-09-18.
- Trials on file
- 44
- Active
- 3
- Active phase 3
- 0
- Participants in active trials
- 2,318
- Sponsors
- 10
- Scheduled readouts
- 3
Scheduled to report
Dates are filed by the sponsor and move often. Each links to its own record and change history.
| Est. completion | Trial | Phase | Participants |
|---|---|---|---|
| 2026-09-18 | iGlarLixi CGM Study in Chinese T2D Individuals After OADs NCT06671587 · Sanofi | P4 | 678 |
| 2027-06-30 | Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes NCT07173712 · Yanbing Li | P4 | 324 |
| 2027-06-30 | Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents NCT07307235 · Shanghai Zhongshan Hospital | P4 | 1,316 |
All trials on file
Every registered trial of lixisenatide grouped under type 2 diabetes, largest first. Grouping follows the registry’s own condition wording.
See the full record for lixisenatide, or every molecule being studied in type 2 diabetes. These are registered trials, nothing more. Most drugs tested in a new condition never get approved for it, and plenty of these will report nothing useful.